Chancellor Jeremy Hunt has announced a comprehensive ‘Life Sci for Growth’ package of support for the UK life sciences sector, designed to grow the economy through improving regulation around clinical trials, manufacturing, skills and infrastructure.
We are excited to report that PharmaMedic's Managing Director, Dr Malcolm Barratt-Johnson has received a Global Fellow in Medicines Development (GFMD) award from the respected GMDP Academy.
The European Medicines Agency (EMA) has published its annual report for 2022, highlighting its challenges and successes in a year that saw it face ongoing and new public health emergencies.
With Mental Health Awareness Week 2023 having taken place from 15-21 May and focusing on anxiety, what advances have there been in this field to support those with mental health conditions? We examine the status of mental health therapy demand in the UK and whether the provision of digitally enabled treatments could be one way to help ease waiting times.
Decentralised clinical trials (DCTs) are being used increasingly in the pharma industry for clinical research and the US Food and Drug Administration (FDA) has published draft guidance for those carrying out trials at non-traditional investigation sites.
Cancer diagnosis and treatment are set to be accelerated with the opening of England’s first Integrated Pathology Unit (IPU). The new facility will apply pioneering digital imaging and artificial intelligence to pathology, assisting clinical trial research programmes focused on developing tests for cancer.
Discussions are beginning on the next iteration of the UK’s voluntary scheme for branded medicines, pricing and access (VPAS) and the Association of the British Pharmaceutical Industry (ABPI) has set out its stall to government. It has published a four-point proposal for a Voluntary Scheme for Pricing, Access and Growth (VPAG), designed to reignite competitiveness and boost innovation in the life sciences sector, thereby improving health outcomes and the wider economy.
The European Commission’s (EC) long-awaited proposals for reforming pharma legislation have been published. The main thrust of the proposals is to create a single EU market for medicines to replace existing fragmentation and improve access for EU citizens.
The 2023 annual conference of the UK’s Association of the British Pharmaceutical Industry (ABPI) at the end of April had a theme of Growing the UK as a Global Hub for Life Sciences.
The UK’s National Institute for health and Care Excellence (NICE) has announced that it will be working closely with the Canadian Agency for Drugs and Technologies in Health (CADTH) and the US Institute for Clinical and Economic Review (ICER) to find common ground and smooth processes around the handling of confidential information about health technologies.
